Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants of both genders who are in generally good health will be eligible for this study. For infants to be enrolled, the parents/legal representatives need to provide written informed consent and to be available for all study visits.~Exclusion Criteria:~* Serious, acute, or chronic illnesses are reasons for exclusion.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- MenACWY3 (Type: EXPERIMENTAL): Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
- MenACWY4 (Type: EXPERIMENTAL): All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
- Routine Vaccines (Type: PLACEBO_COMPARATOR): Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).